Pediatrics

MPR Weekly Dose Podcast #126

Emergency use authorization for intradermal administration of Jynneos; treatment approved for endometriosis pain; Amazon among the companies to receive a FDA Warning Letter for selling unapproved drugs; a diabetes drug is found to contain a possible carcinogen; and a new scale that measures peripheral impedance and pulse rate.

Benlysta Approval Expanded to Include Pediatric Lupus Nephritis

The Food and Drug Administration (FDA) has expanded the approval of Benlysta (belimumab) to include pediatric patients 5 to 17 years of age with active lupus nephritis who are receiving standard therapy. Benlysta, a B-lymphocyte stimulator (BLyS)-specific inhibitor, is also indicated for the treatment of patients 5 years of age and older with active systemic…